Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity

Sherif M. Shoieb, Ahmed A. El-Sherbeni and Ayman O. S. El-Kadi
Drug Metabolism and Disposition February 2019, 47 (2) 67-70; DOI: https://doi.org/10.1124/dmd.118.084657
Sherif M. Shoieb
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada S.M.S., A.O.S.E.-K.; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada A.A.E.-S.; and Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt A.A.E.-S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed A. El-Sherbeni
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada S.M.S., A.O.S.E.-K.; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada A.A.E.-S.; and Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt A.A.E.-S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmed A. El-Sherbeni
Ayman O. S. El-Kadi
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada S.M.S., A.O.S.E.-K.; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada A.A.E.-S.; and Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt A.A.E.-S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    R- and S-enantiomers of 19-HETE. Both enantiomers represent an example of stereoisomerism of P450-mediated arachidonic acid metabolites. Incorporation of an hydroxyl group in the carbon skeleton of arachidonic acid generates a chiral center, hence there are two enantiomers for each HETE metabolite.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Inhibitory effect of 19(R)-HETE and 19(S)-HETE on EROD activity mediated by human recombinant CYP1B1. In 96-well solid black polystyrene plates, the reaction mixture containing 100 mM potassium phosphate (pH 7.4) buffer supplemented with 5 mM magnesium chloride hexahydrate and 1 pmol of human CYP1B1 was incubated with 10–100 nM 7-ER. In addition, either 19(R)-HETE (A) or 19(S)-HETE (B) at 0, 5, 10, 20, or 40 nM concentration was added to the reaction. The reaction was initiated by the addition of 100 μl of 2 mM NADPH, the fluorescent signal related to the formation of resorufin was measured every minute (excitation and emission wavelengths of 550 and 585 nm, respectively) for 30 minutes at 37°C using a BioTek Synergy H1 Hybrid. The quantity of formed resorufin was measured by the construction of standard curve of 0–200 nM resorufin dissolved in the same incubation buffer. Each point represents the mean of six independent experiments ± S.E.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Dixon plots representing the inhibitory effect of 19(R)-HETE and 19(S)-HETE on EROD activity mediated by human recombinant CYP1B1. The y-axis represents the reciprocal of EROD activity expressed in picomoles of resorufin/picomoles CYP1B1/minute and the x-axis represents 19(R)-HETE (A) or 19(S)-HETE (B) concentrations in nanomolar concentrations in the presence of increasing concentration of the substrate 7-ER (10–100 nM). Each point represents the mean of six independent experiments ± S.E.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    The mean values and S.E. of kinetic parameters of resorufin formation by human recombinant CYP1B1 in the absence and presence of 19(R)-HETE or 19(S)-HETE

    Results are presented as mean and S.E., of at least three individual experiments. Km, Vmax and Ki mean ± S.E. were determined by the Enzyme Kinetics module of GraphPad Prism, version 5.01.

    KmVmaxKi
    19(R)-HETE19(S)-HETE
    nMpmol/pmol P450 per minutenMnM
    86.6 ± 10.416.7 ± 1.189.1 ± 11.537.3 ± 5.5
    • View popup
    TABLE 2

    The mean values and S.E. of 19(R)-HETE or 19(S)-HETE levels calculated as a percentage of the metabolite level at the beginning of the experiment (T0)

    Data are represented as mean ± S.E. where n = 3.

    19(R/S)-HETE levels as a percentage of their levels at zero time (%)
    Time interval (Tminute)T0T10T20T30
    19(R)-HETE100 ± 17.198.6 ± 7.896.3 ± 1.398.5 ± 8.9
    19(S)-HETE100 ± 5.999.7 ± 1.3100.1 ± 0.998.9 ± 4.6

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Figures -

      Supplemental Figure 1 - Representative LC-MS chromatograms showing the peaks of 19(R)-HETE and internal standard at the start of the experiment (a), after 10 min (b), 20 min (c) and 30 min (d)

      Supplemental Figure 2 - Representative LC-MS chromatograms showing the peaks of 19(S)-HETE and internal standard at the start of the experiment (a), after 10 min (b), 20 min (c) and 30 min (d).

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 47 (2)
Drug Metabolism and Disposition
Vol. 47, Issue 2
1 Feb 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

19-HETE Enantiomers Noncompetitively Inhibit CYP1B1

Sherif M. Shoieb, Ahmed A. El-Sherbeni and Ayman O. S. El-Kadi
Drug Metabolism and Disposition February 1, 2019, 47 (2) 67-70; DOI: https://doi.org/10.1124/dmd.118.084657

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

19-HETE Enantiomers Noncompetitively Inhibit CYP1B1

Sherif M. Shoieb, Ahmed A. El-Sherbeni and Ayman O. S. El-Kadi
Drug Metabolism and Disposition February 1, 2019, 47 (2) 67-70; DOI: https://doi.org/10.1124/dmd.118.084657
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics